Skip to main content
. 2021 Feb 10;49:101187. doi: 10.1016/j.molmet.2021.101187

Figure 3.

Figure 3

Effects of FOXO1 inhibitor compound 10 in STZ lean mice. STZ-induced diabetic male mice were treated by vehicle, compound 10 (32 mg/kg/dose), FGF21 (0.45 mg/kg), or both compound 10 and FGF21. (A) Ad libitum blood glucose levels were measured 1 h after dosing. (B) Blood glucose levels were measured during an OGTT performed on day 11. (C–H) Blood glucose (C) and plasma levels of insulin (D), triglycerides (G), and total cholesterol (H) were measured after a 6-h fast on indicated days. Fasting glucose and insulin levels were used to calculate HOMA-IR (E) and HOMA-β (F). (I) Liver TG content was measured on day 11. (J) AST level was measured in ad libitum plasma on day 9. (K) Change in body weight on day 10 compared to day 0 and (L) perigonadal fat pad weight on day 11 were recorded. N = 5–6 per group. Data are Mean ± SEM. ∗, ∗∗, ∗∗∗, ∗∗∗∗: p < 0.05, 0.01, 0.001, 0.0001 vs. vehicle control by two-way ANOVA. ˆ: p < 0.05 between indicated groups by two-way ANOVA.